(Q46455135)

22 December 2017

title

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma (English)

1 reference

22 December 2017

Markus Peck-Radosavljevic

0 references

1 reference

9

1 reference

22 December 2017

Michael Trauner

8

object named as

Michael Trauner

1 reference

22 December 2017

Ivo W Graziadei

4

object named as

Ivo Graziadei

1 reference

22 December 2017

author name string

Wolfgang Sieghart

1

1 reference

22 December 2017

Florian Hucke

2

1 reference

22 December 2017

Matthias Pinter

3

1 reference

22 December 2017

Wolfgang Vogel

5

1 reference

22 December 2017

Christian Müller

6

1 reference

22 December 2017

Harald Heinzl

7

1 reference

22 December 2017

language of work or name

English

0 references

publication date

3 May 2013

1 reference

22 December 2017

published in

Hepatology

1 reference

22 December 2017

volume

57

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

2261-2273

1 reference

22 December 2017

cites work

Global cancer statistics

1 reference

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

21 January 2018

1 reference

Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma.

21 January 2018

1 reference

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

21 January 2018

1 reference

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis

21 January 2018

1 reference

Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma

21 January 2018

1 reference

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib

21 January 2018

1 reference

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions.

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models

21 January 2018

1 reference

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

21 January 2018

1 reference

Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.26256

1 reference

22 December 2017

1 reference

22 December 2017